{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:39:32Z","timestamp":1788867572272,"version":"build-2803163510"},"reference-count":24,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Individuals with type 2 diabetes (T2D) have high rates of mortality following myocardial infarction (MI). Hospitalization is an opportunity to initiate or continue evidence-based treatment to reduce risk in individuals with T2D and acute coronary syndrome (ACS).<\/jats:p><\/jats:sec>Objective<\/jats:title>To determine patterns of evidence-based medication use during the period of transition from admission to discharge after hospitalization for MI or coronary revascularization among individuals with T2D and ACS.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This retrospective cohort study used data from the Centers for Medicare &amp;amp; Medicaid Services (CMS) for January 1, 2018, to June 30, 2020. Medicare beneficiaries older than 18 years with T2D with a qualifying hospitalization were included. Individuals were followed before admission (90 days prior), at discharge (\u226490 days), and after discharge (91-180 days after) from a hospitalization for MI or coronary revascularization. Data analysis was performed in June 2023.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Demographic data (race, sex, rural vs urban location of care, and comorbidities) were abstracted from CMS data using Master Beneficiary and Summary Files and International Statistical Classification of Diseases, Tenth Revision<\/jats:italic> codes.<\/jats:p><\/jats:sec>Main Outcome and Measures<\/jats:title>Medicare Part D prescription fill records were examined for the following agents: (1) angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), or angiotensin receptor\u2013neprilysin inhibitors (ARNIs); (2) \u03b2-blockers; (3) platelet adenosine diphosphate receptor inhibitors (P2Y12<\/jats:sub>Is); (4) statins or proprotein convertase subtilisin\/kexin type 9 inhibitors (PCSK9Is); and (5) glucagon-like peptide 1 receptor agonists (GLP-1RAs) or sodium glucose cotransporter 2 inhibitors (SGLT2Is). Logistic regression analysis was used to examine the association between covariates and lack of prescription fills in the postdischarge period.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 188\u202f651 eligible Medicare beneficiaries with T2D and hospitalization for MI or coronary revascularization were identified. Their median age was 73.0 (IQR, 67.0-79.0) years, and more than half (111\u202f982 [59.4%]) were men; 18\u202f383 (9.7%) were Black and 153\u202f461 (81.3%) were White. Not filling a cardiovascular medication after hospitalization was associated with not filling that medication at the time of discharge (adjusted risk ratio, 0.27 [95% CI, 0.27-0.28] for ACEIs, ARBs, or ARNIs; 0.24 [0.24-0.25] for \u03b2-blockers; 0.20 [0.19-0.20] for P2Y12<\/jats:sub>Is; 0.31 [0.31-0.32] for statins or PCSK9Is; and 0.27 [0.26-0.28] for SGLT2Is or GLP-1RAs).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study of Medicare beneficiaries with T2D, longer-term medication use following hospitalization for MI was associated with medication use at the time of discharge. These findings highlight the critical importance of this period to optimize preventive care for these high-risk individuals. Further implementation science research is needed to develop strategies to improve use of these evidence-based medications.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.47102","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T16:33:38Z","timestamp":1732725218000},"page":"e2447102","source":"Crossref","is-referenced-by-count":5,"title":["Prescription Fills Among Patients With Type 2 Diabetes After Hospitalization for Acute Coronary Syndrome"],"prefix":"10.1001","volume":"7","author":[{"given":"Michelle D.","family":"Kelsey","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Duke University, Durham, North Carolina"},{"name":"Duke Clinical Research Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassie","family":"Ford","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Oakes","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Soneji","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayden B.","family":"Bosworth","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"},{"name":"Department of Population Health Sciences, Duke University, Durham, North Carolina"},{"name":"Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, Durham, North Carolina"},{"name":"Division of General Internal Medicine, Duke University School of Medicine, Durham, North Carolina"},{"name":"School of Nursing, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha J.","family":"Pagidipati","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Duke University, Durham, North Carolina"},{"name":"Duke Clinical Research Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"issue":"10","key":"zoi241336r2","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1161\/CIRCULATIONAHA.114.014796","article-title":"Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) Registry.","volume":"132","author":"Cavender","year":"2015","journal-title":"Circulation"},{"issue":"9","key":"zoi241336r3","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1008862","article-title":"Diabetes mellitus, fasting glucose, and risk of cause-specific death.","volume":"364","author":"Rao Kondapally Seshasai","year":"2011","journal-title":"N Engl J Med"},{"key":"zoi241336r4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/978-3-030-51089-3","article-title":"Diabetes mellitus and acute myocardial infarction: impact on short and long-term mortality.","volume":"1307","author":"Milazzo","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"zoi241336r5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ijcard.2016.04.182","article-title":"A systematic review and meta-regression of temporal trends in the excess mortality associated with diabetes mellitus after myocardial infarction.","volume":"217","author":"Bauters","year":"2016","journal-title":"Int J Cardiol"},{"issue":"1","key":"zoi241336r6","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12933-022-01655-w","article-title":"Diabetes mellitus duration and mortality in patients hospitalized with acute myocardial infarction.","volume":"21","author":"Baviera","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"zoi241336r7","doi-asserted-by":"publisher","DOI":"10.1177\/14791641221113788","article-title":"Impact of diabetes on long-term all-cause re-hospitalization after revascularization with percutaneous coronary intervention.","volume":"19","author":"Hansen","year":"2022","journal-title":"Diab Vasc Dis Res"},{"issue":"7","key":"zoi241336r8","doi-asserted-by":"publisher","first-page":"e294","DOI":"10.1161\/CIR.0000000000000691","article-title":"Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update.","volume":"140","author":"Dunlay","year":"2019","journal-title":"Circulation"},{"key":"zoi241336r9","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.2337\/dc23-S010","article-title":"10: Cardiovascular disease and risk management: standards of care in diabetes\u20142023.","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"issue":"9","key":"zoi241336r10","doi-asserted-by":"publisher","first-page":"e722","DOI":"10.1161\/CIR.0000000000001040","article-title":"Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association.","volume":"145","author":"Joseph","year":"2022","journal-title":"Circulation"},{"issue":"18","key":"zoi241336r11","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/j.jacc.2022.02.046","article-title":"Guidelines for cardiovascular risk reduction in patients with type 2 diabetes: JACC guideline comparison.","volume":"79","author":"Kelsey","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"zoi241336r12","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1161\/CIRCULATIONAHA.119.041730","article-title":"Use of guideline-recommended risk reduction strategies among patients with diabetes and atherosclerotic cardiovascular disease.","volume":"140","author":"Arnold","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"zoi241336r13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.016835","article-title":"Gaps in evidence-based therapy use in insured patients in the United States with type 2 diabetes mellitus and atherosclerotic cardiovascular disease.","volume":"10","author":"Nelson","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"zoi241336r14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.48030","article-title":"Use of lipid-, blood pressure-, and glucose-lowering pharmacotherapy in patients with type 2 diabetes and atherosclerotic cardiovascular disease.","volume":"5","author":"Nelson","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi241336r16","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/MLR.0000000000001216","article-title":"Validity of race and ethnicity codes in Medicare administrative data compared with gold-standard self-reported race collected during routine home health care visits.","volume":"58","author":"Jarr\u00edn","year":"2020","journal-title":"Med Care"},{"issue":"1","key":"zoi241336r17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12872-016-0283-6","article-title":"Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction.","volume":"16","author":"Halvorsen","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"issue":"2","key":"zoi241336r18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jamacardio.2016.0001","article-title":"Timing of first postdischarge follow-up and medication adherence after acute myocardial infarction.","volume":"1","author":"Faridi","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"10","key":"zoi241336r19","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1136\/heartjnl-2014-306754","article-title":"Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction.","volume":"101","author":"Shore","year":"2015","journal-title":"Heart"},{"issue":"7","key":"zoi241336r20","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1001\/jamainternmed.2018.0783","article-title":"Trends in platelet adenosine diphosphate P2Y12 receptor inhibitor use and adherence among antiplatelet-naive patients after percutaneous coronary intervention, 2008-2016.","volume":"178","author":"Dayoub","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"17","key":"zoi241336r21","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1001\/archinte.166.17.1842","article-title":"Impact of medication therapy discontinuation on mortality after myocardial infarction.","volume":"166","author":"Ho","year":"2006","journal-title":"Arch Intern Med"},{"issue":"4","key":"zoi241336r22","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1001\/jama.285.4.430","article-title":"Early statin treatment following acute myocardial infarction and 1-year survival.","volume":"285","author":"Stenestrand","year":"2001","journal-title":"JAMA"},{"issue":"11","key":"zoi241336r23","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1111\/jgs.15144","article-title":"Secondary prevention medication use after myocardial infarction in U.S. nursing home residents.","volume":"65","author":"Zullo","year":"2017","journal-title":"J Am Geriatr Soc"},{"issue":"19","key":"zoi241336r24","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.010203","article-title":"Fifteen-year trends in management and outcomes of non\u2013ST-segment\u2013elevation myocardial infarction among black and white patients: the ARIC Community Surveillance study, 2000\u20132014.","volume":"7","author":"Arora","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"zoi241336r1","unstructured":"National Diabetes Statistics Report: prevalence of both diagnosed and undiagnosed diabetes. Centers for Disease Control and Prevention. 2023. Accessed October 23, 2023. https:\/\/www.cdc.gov\/diabetes\/php\/data-research\/index.html"},{"key":"zoi241336r15","unstructured":"2010 Rural-urban commuting area (RUCA) codes. US Dept of Agriculture. Accessed October 2, 2023. https:\/\/www.ers.usda.gov\/data-products\/rural-urban-commuting-area-codes\/documentation\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2827167\/kelsey_2024_oi_241336_1732127338.84888.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T16:33:41Z","timestamp":1732725221000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2827167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.47102","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]}}}